Long-term efficacy and safety of renal denervation: an update from registries and randomised trials
Hypertension remains the leading treatable global cause of mortality due to high incidence and poor control rates despite of safe and effective drug therapy. Animal studies do not support functional nerve regrowth after RF-RDN and accordingly clinical evidence verify that RDN leads to durable BP red...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Blood Pressure |
| Online Access: | http://dx.doi.org/10.1080/08037051.2023.2266664 |
| _version_ | 1797638454041903104 |
|---|---|
| author | Kyriakos Dimitriadis Roland E. Schmieder Panagiotis Iliakis Laura Nickel Konstantinos Tsioufis Joachim Weil |
| author_facet | Kyriakos Dimitriadis Roland E. Schmieder Panagiotis Iliakis Laura Nickel Konstantinos Tsioufis Joachim Weil |
| author_sort | Kyriakos Dimitriadis |
| collection | DOAJ |
| description | Hypertension remains the leading treatable global cause of mortality due to high incidence and poor control rates despite of safe and effective drug therapy. Animal studies do not support functional nerve regrowth after RF-RDN and accordingly clinical evidence verify that RDN leads to durable BP reduction. Renal denervation is safe, as up to 36 months after the procedure, there are no statistically significant difference in procedure-related adverse events, deterioration of renal function and adverse cardiovascular outcome Renal denervation is efficient in reducing BP in patients with no drug therapy, independently of the number of antihypertensive drugs and phenotype of patient. This sustained and safe reduction in BP observed up to 36 months after RDN could be associated with lower rates of renal and cardiovascular events. |
| first_indexed | 2024-03-11T13:03:42Z |
| format | Article |
| id | doaj.art-addaf93aaee44c71937dba72c4bf749e |
| institution | Directory Open Access Journal |
| issn | 0803-7051 1651-1999 |
| language | English |
| last_indexed | 2024-03-11T13:03:42Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Blood Pressure |
| spelling | doaj.art-addaf93aaee44c71937dba72c4bf749e2023-11-03T16:27:52ZengTaylor & Francis GroupBlood Pressure0803-70511651-19992023-12-0132110.1080/08037051.2023.22666642266664Long-term efficacy and safety of renal denervation: an update from registries and randomised trialsKyriakos Dimitriadis0Roland E. Schmieder1Panagiotis Iliakis2Laura Nickel3Konstantinos Tsioufis4Joachim Weil5First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General HospitalDepartment of Nephrology and Hypertension, University Hospital Erlangen, Friedrich Alexander University Erlangen NürnbergFirst Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General HospitalMedizinische Klinik II, Sana Kliniken Lübeck GmbHFirst Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General HospitalMedizinische Klinik II, Sana Kliniken Lübeck GmbHHypertension remains the leading treatable global cause of mortality due to high incidence and poor control rates despite of safe and effective drug therapy. Animal studies do not support functional nerve regrowth after RF-RDN and accordingly clinical evidence verify that RDN leads to durable BP reduction. Renal denervation is safe, as up to 36 months after the procedure, there are no statistically significant difference in procedure-related adverse events, deterioration of renal function and adverse cardiovascular outcome Renal denervation is efficient in reducing BP in patients with no drug therapy, independently of the number of antihypertensive drugs and phenotype of patient. This sustained and safe reduction in BP observed up to 36 months after RDN could be associated with lower rates of renal and cardiovascular events.http://dx.doi.org/10.1080/08037051.2023.2266664 |
| spellingShingle | Kyriakos Dimitriadis Roland E. Schmieder Panagiotis Iliakis Laura Nickel Konstantinos Tsioufis Joachim Weil Long-term efficacy and safety of renal denervation: an update from registries and randomised trials Blood Pressure |
| title | Long-term efficacy and safety of renal denervation: an update from registries and randomised trials |
| title_full | Long-term efficacy and safety of renal denervation: an update from registries and randomised trials |
| title_fullStr | Long-term efficacy and safety of renal denervation: an update from registries and randomised trials |
| title_full_unstemmed | Long-term efficacy and safety of renal denervation: an update from registries and randomised trials |
| title_short | Long-term efficacy and safety of renal denervation: an update from registries and randomised trials |
| title_sort | long term efficacy and safety of renal denervation an update from registries and randomised trials |
| url | http://dx.doi.org/10.1080/08037051.2023.2266664 |
| work_keys_str_mv | AT kyriakosdimitriadis longtermefficacyandsafetyofrenaldenervationanupdatefromregistriesandrandomisedtrials AT rolandeschmieder longtermefficacyandsafetyofrenaldenervationanupdatefromregistriesandrandomisedtrials AT panagiotisiliakis longtermefficacyandsafetyofrenaldenervationanupdatefromregistriesandrandomisedtrials AT lauranickel longtermefficacyandsafetyofrenaldenervationanupdatefromregistriesandrandomisedtrials AT konstantinostsioufis longtermefficacyandsafetyofrenaldenervationanupdatefromregistriesandrandomisedtrials AT joachimweil longtermefficacyandsafetyofrenaldenervationanupdatefromregistriesandrandomisedtrials |